Aldeyra Therapeutics (ALDX) Cash from Investing Activities (2014 - 2025)

Aldeyra Therapeutics' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at $16.0 million for Q4 2025.

• Quarterly Cash from Investing Activities rose 1123.1% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $40.4 million (up 657.97% YoY) and the FY2025 annual result came in at $47.7 million, up 206.28% from the prior year.
• Cash from Investing Activities was $16.0 million for Q4 2025 at Aldeyra Therapeutics, down from $25.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $30.0 million in Q1 2023 and bottomed at -$58.0 million in Q1 2022.
• A 5-year average of $204156.9 and a median of $2.6 million in 2021 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 743325.39% — and 2025, when it surged 1123.1%.
• Aldeyra Therapeutics' Cash from Investing Activities stood at -$7806.0 in 2021, then surged by 345987.78% to $27.0 million in 2022, then advanced by 11.11% to $30.0 million in 2023, then sank by 105.21% to -$1.6 million in 2024, then jumped by 1123.1% to $16.0 million in 2025.
• Business Quant data shows ALDX's Cash from Investing Activities at $16.0 million in Q4 2025, $25.0 million in Q3 2025, and -$554126.0 in Q2 2025.